A benign circle: how a combination of factors has reduced HIV infections in one of the hardest-hit parts of Africa

But migrants to area remain at higher risk

Mary Grabowski at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com
Gus Cairns
Published: 14 February 2017

HIV incidence has started to tumble in one of the best-studied groups of people in Africa, the Conference on Retroviruses and Opportunistic Infections (CROI 2017) heard in Seattle today. The annual infection rate has fallen 40% in the last four years, the conference was told. A combination of factors, including wider availability of antiretroviral therapy, increased male circumcision, and later age of sexual debut in young people, all appear to be contributing to this decline.

Presenter Mary Grabowski confirmed that this is the first time a population-level decline in incidence in the Rakai cohort has been observed.

Background

The Rakai Community Cohort Study, in a corner of southern Uganda, is probably the longest-studied group of people with, and at risk of, HIV in a low-income setting. This study, which dates from 1994-5 and was built upon an even older one dating from 1989, enrols every consenting adult aged 15-49 living in a 50-village territory and regularly ‘tops itself up’ with new members, keeping its participants at a level of about 12,000. Rakai has hosted many pioneering HIV studies ranging from the first study to show conclusively that HIV treatment reduced infectiousness to one of the three landmark randomised studies of medical male circumcision for HIV prevention.

Rakai was chosen as a site because it was the area first and hardest hit by HIV in Uganda; in 1989 it had an HIV prevalence of over 20%, only surpassed since by the later hyper-epidemic in southern Africa in the late 1990s. HIV prevalence fell to 13% by the mid-1990s and has stayed pretty steadily at that level ever since. At the time the fall in prevalence was ascribed to the success of behaviour change programmes, but was probably more due to deaths among the first wave of people infected during the peak of HIV incidence in the mid-1980s.

Incidence – the rate of new infections among a population – is a better guide to whether HIV epidemics are truly growing or shrinking, though true incidence is quite difficult to establish as it is affected by testing rates. However, in situations with an established HIV epidemic and high rates of testing, as in Rakai, new diagnoses are a reasonable surrogate for incidence. And in the last four years there is no doubt that it has decreased.

The present study

Data were collected between 1999 and 2016 in 12 surveys from 30 communities in the Rakai Community Cohort. Incidence was compared at seven particular timepoints between 2004 and 2016 and compared with incidence prior to 2004. Over this period, 33,937 people took part; including 17,870 initially HIV-negative people and 16,067 with HIV. Of the HIV-negative people, 931 (5.2%) tested HIV-positive during 94,427 person-years of follow-up, an annual incidence of just under 1%.

Antiretroviral therapy (ART) started to become available in Rakai by 2004 and by 2016, 69% of people with HIV in the cohort were taking ART. This has led to an increase in the proportion of people in the community who have HIV and are virally suppressed; this proportion, including the undiagnosed and those not on ART, rose from 42% in 2009 to 75% by 2016 (and thus achieved the UNAIDS 90-90-90 target).

At the same time, the rollout programme of medical male circumcision meant that the proportion of men who were circumcised rose from 15% in 1999 to 59% in 2016. Male circumcision coverage increased from 15% in 1999 to 59% by 2016.

A third significant change happened during the same period; young people started having sex later. The proportion of young people aged 15-19 who reported not yet starting sex rose from 30% to 55% over the 1999-2016 study period.

HIV incidence was a steady 1.17% a year over most of the study period, from 2000 to 2010. But after that it started to fall. By 2012 it was 0.8% a year and by 2016 it was 0.66% a year, a 42% decline. Incidence fell further in men (by 54%) than in women (by 32%). Presenter Mary Grabowski said this might be due to men reaping the benefits both of ART and of medical male circumcision.

Grabowski confirmed that this is the first time a population-level decline in incidence in the Rakai cohort has been observed.

At the same time, however, prevalence has stayed stuck at a remarkably steady 13%, exactly what it was in 1994. This is probably due to the fact that ART is prolonging people’s lives and so the net total of people with HIV in the population is staying the same.

Migrants are more at risk within Africa

A second study looked at migrants to the Rakai area and compared HIV incidence in them versus permanent residents. Migrants were defined as a person “who moves to a new community with intention to stay”. Among the 13,991 people in this study, one third (4571 people) met this definition.

Annual HIV incidence was 0.88% in permanent residents, 0.97% in long-term settled migrants and 1.6% in recently arrived migrants.

After statistical adjustment, it was found that in women, recently arrived migrants were 60% more likely to become infected with HIV than permanent residents, but settled migrants no more likely. Recently arrived migrant men were 34% more likely to become infected, but this was not statistically significant.

This study confirms that in east Africa, as much as in other parts of the world, being a new arrival within a community is a risk factor for HIV in itself.

References

Grabowski MK et al. Combination HIV prevention and HIV incidence in Rakai, Uganda. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, abstract 34LB, 2017.

View the abstract on the conference website.

View a webcast of this presentation on the conference website.

Olawore OM et al. Migration, gender, and HIV incidence in Rakai, Uganda. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, abstract 1015, 2017.

View the abstract on the conference website.

View a webcast of this presentation on the conference website.

E-atlas

Uganda

Find details of HIV services in Uganda, the latest news from the country, and a selection of resources from local organisations.

Find out more about Uganda >

NAM's coverage of CROI 2017 has been made possible thanks to support from Janssen and ViiV Healthcare.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.